International BPDCN Day 2025: Advancing Awareness, Research, and Hope for a Rare Hematologic Cancer
BPDCN International Registry shared a post on LinkedIn:
“Today, on International BPDCN Day,
We unite to shed light on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare and aggressive hematologic malignancy that often remains underdiagnosed due to its rarity and complex presentation.
BPDCN predominantly affects the skin, bone marrow, and lymph nodes, posing significant diagnostic and therapeutic challenges. Despite advances in hematology, much remains to be understood about its pathogenesis, optimal treatment strategies, and long-term outcomes. Greater awareness and focused research are critical to improving the prognosis for patients worldwide.
In line with this mission, we are proud to celebrate our registry (NCT05430971), lead by Principal Investigator Astghik Voskanyan. Initiated by the Immune Oncology Research Institute, our registry has reached cancer centers around the world including USA, Egypt, Canada, Italy, Georgia, Turkey, UK, Armenia, India, Iraq, Kuwait, Cyprus and Romania.
Focused on collecting comprehensive data on BPDCN cases, we aim to bridge the gap in knowledge and contribute to global research efforts in finding better treatment strategies for BPDCN patients.
We invite researchers, clinicians, and their institutions to join us in this endeavor, fostering a global network dedicated to tackling BPDCN.
Let us use International BPDCN Day as an opportunity to amplify our collective efforts, inspire new collaborations, and give hope to patients and their families. Together, we can make a meaningful difference in the fight against BPDCN.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023